Extension usage examples:
Here's how our browser extension sees the article:
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial - PubMed
Source: pubmed.ncbi.nlm.nih.gov
Article summary:
1. A phase 1 trial was conducted to evaluate the safety and efficacy of tumor-infiltrating lymphocyte (TIL) treatment for anti-PD-1-resistant metastatic lung cancer.
2. The primary end point was safety, and secondary end points included objective response rate, duration of response, and T cell persistence.
3. Results showed that TIL treatment was generally safe and clinically active, suggesting it may be a new treatment strategy in metastatic lung cancer.
Article analysis:
The article is overall reliable and trustworthy as it provides detailed information on the study design, methods used, results obtained, and conclusions drawn from the data. The authors have also provided a comprehensive list of affiliations for all authors involved in the study. Furthermore, they have provided a clear conflict of interest statement which states that none of the authors have any relevant conflicts to disclose.
However, there are some potential biases that should be noted when evaluating this article. Firstly, the study is limited by its small sample size (n=20), which may not be representative of the general population or provide sufficient evidence to draw definitive conclusions about the efficacy of TIL treatment for anti-PD-1-resistant metastatic lung cancer. Additionally, while the authors do mention possible risks associated with TIL treatment such as severe toxicity (up to 17%), they do not provide any further details on what these risks might entail or how they can be managed or avoided. Finally, while the authors do discuss potential benefits associated with TIL treatment such as complete responses lasting up to 1.5 years later in two patients, they do not explore any potential counterarguments or alternative treatments that could be considered instead of TIL therapy for this condition.